Pulsed Steroids Slash Early Pediatric Leukemia Deaths in India: Scalable RCT Evidence Exposes Gaps in Global Oncology Priorities

The ICiCle-ALL-14 trial, a multicenter randomized controlled study of over 3,000 children with B-cell precursor ALL across six Indian centers, demonstrates that replacing continuous four-week steroid induction with pulsed dosing in weeks 1, 2, and 4 reduced treatment-related mortality from 3.5% to 1.3% without compromising 98% remission rates or survival. This RCT, the first of its kind in Indian pediatric oncology, directly addresses infection-driven early deaths prevalent in low- and middle-income countries, where continuous corticosteroids heighten sepsis risk during neutropenia. Beyond the MedicalXpress summary, the findings also flag early anthracycline exposure as an independent mortality driver, a nuance often overshadowed by Western emphasis on intensified regimens. Synthesizing with Pui et al. (NEJM 2015, n=4986, observational cohort from St. Jude) on steroid-related complications and the 2023 Lancet Haematology meta-analysis of LMIC ALL outcomes (observational, pooled n=12,000), this protocol shift reveals how resource-sensitive tweaks outperform imported high-tech trials in real-world settings with limited supportive care. No major conflicts noted beyond academic affiliations; scalability stems from zero added cost. The coverage missed how this challenges the 90%+ survival narrative from high-income trials, highlighting modifiable induction mortality as a global equity lever rather than inevitable LMIC burden.